ClinicalTrials.gg
CompletedNCT02387359IBS-CUpdated Oct 20, 2026Results posted

The Plecanatide Irritable Bowel Syndrome With Constipation Safety and Efficacy Study (IBS-C)

A Phase 3 interventional study of Plecanatide and Placebo in Irritable Bowel Syndrome Characterized by Constipation, sponsored by Bausch Health Americas, Inc.. Completed at 155 sites in United States. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-10-20.

Sponsored by Bausch Health Americas, Inc. (part of Bausch Health Companies Inc.) · Phase 3, Interventional, and Treatment

Updated Oct 20, 2026Title changed6 sites added+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,054
Allocation
Randomized
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies testing plecanatide in Constipation — none open to participants now, 1 under way, none of them phase 3. plecanatide · Constipation.

Enrollment
5th of 12
1,054 · median 800
Started
2014
with 1 other
Phase 3
6 of 12
none open now
Registered
7th of 12
by date
Lead sponsor
11 of 12
Bausch Health Americas, Inc.

Among the 12 studies testing plecanatide in Constipation, this one is the 5th largest by enrollment, is one of 2 that started in 2014, is one of 6 in phase 3, and was the 7th registered.

Constipation

1,047 studies on the registry are indexed under Constipation; 161 are open to participants now.

Browse Constipation studies →

Open to participants now

None of the 12 studies testing plecanatide in Constipation is open now. The open studies under Constipation, anywhere →

Where they have run

About plecanatide

plecanatide: first FDA approval 2017 (TRULANCE). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 99 Constipation studies recruiting now, 32 (32%) set no upper age limit and 52 (53%) stop at 75 or younger; 17 take children under 18; 28 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 12 studies testing plecanatide in Constipation as a file.
02

Study summary

This study in patients with IBS-C is a randomized, double-blind, placebo-controlled, parallel-group clinical trial with 12 weeks of study drug therapy.

Read the detailed description

This study in patients with IBS-C is a randomized, double-blind, placebo-controlled, parallel-group clinical trial with 12 weeks of study drug therapy.

Screening/Baseline: Patients will undergo an up to 28-day Screening/Baseline period to allow for any necessary diagnostic procedures, allow for required washout of medications and to determine study eligibility. If otherwise eligible based on screening criteria, patients will undergo a 2-week baseline assessment using an electronic diary where they will record daily assessments of bowel movements (BMs), stool consistency (Bristol Stool Form Scale-BSFS), abdominal pain and other IBS-related symptoms. Data from the two-week electronic diary assessment just prior to the randomization visit will be used to confirm IBS-C and study eligibility as well as define the patient's baseline from which change will be determined.

Treatment: Patients who meet all entry criteria will be randomized (1:1:1) to one of three blinded treatment groups on Day 1 of the Treatment period. Patients will take an oral dose of study drug OD for 12 weeks and continue the daily electronic diaries (BMs, rescue medication use, abdominal pain, and other symptoms). During treatment weeks 4, 8, and 12, patients will return to the clinic to undergo safety and efficacy assessments.

Post-Treatment: For 2 weeks after completing dosing, patients will continue to complete daily electronic diaries. Patients will then return to the clinical site for a final follow-up visit during Week 14 following randomization.

The planned duration of participation in this study will be at least 116 days from signing of informed consent through post-treatment or up to approximately 135 days with visit windows considered.

03

Conditions studied

  • Irritable Bowel Syndrome Characterized by Constipation
04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

•Adult patients between the ages of 18 and 85 years (inclusive) with a diagnosis of IBS based on ROME III diagnostic criteria and meeting criteria for diagnosis of the constipation predominant subtype - IBS-C

Exclusion criteria

Exclusion Criteria:

  • Refusal or inability to sign for the trial
  • Refusal or inability to complete daily Episodic (real-time) BM / RM calls, End of Day daily Calls, and/or complete electronic questionnaires
  • > 35 or \< 18
  • Women of child bearing potential who refuse to use an acceptable method of for the duration of the trial
  • Women who are pregnant or lactating
  • Diagnosis of IBS-D or IBS-M
  • Organic or obstructive disease of the small or large intestine
  • Use of laxatives other than the study-supplied rescue medication (Dulcolax®, bisacodyl)
  • Use of a prohibited concomitant medication within the time frame prior to screening outlined in the study protocol for that medication
  • Unstable medical illness
  • > 3X in the absence of a conjugation defect
  • Any laboratory value > 3X ULN unless discussed and approved by the study Medical Monitor
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
1,054 participants (actual)

Study arms

  • Active comparator
    3.0 mg plecanatide

    Plecanatide 3.0 mg dosed daily for 12 weeks

    Drug: Plecanatide

  • Active comparator
    6.0 mg plecanatide

    Plecanatide 6.0 mg dosed daily for 12 weeks

    Drug: Plecanatide

  • Active comparator
    Matching placebo

    Placebo dosed daily for 12 weeks

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Overall Responders - ITT Population

    An Overall Responder was a patient who was a Weekly Responder (i.e., decrease of 30% from baseline for abdominal pain intensity and an increase of at least one complete spontaneous bowel movement in the same week) for at least 6 of the 12 treatment weeks.

    Time frame: 12 Weeks

  2. Number of Abdominal Pain Responders for at Least 6 of 12 Treatment Weeks

    An Abdominal Pain Intensity Responder was a patient who had a decrease of 30% from baseline for abdominal pain intensity. Baseline was the mean of non-missing abdominal pain scores recorded during the 2-week baseline diary assessment period prior to the first dose of study drug.

    Time frame: 12 Weeks

  3. Number of Stool Frequency Responder for at Least 6 of the 12 Treatment Weeks

    A Stool Frequency Responder is defined as a patient who experienced an increase of at least one CSBM (complete spontaneous bowel movement) per week from baseline. Baseline was the mean number of CSBMs recorded during the 2-week baseline diary assessment period prior to the first dose of study drug.

    Time frame: 12 weeks

Secondary outcomes

  1. Number of Sustained Efficacy Responders

    A Sustained Efficacy Responder was a patient who was an Overall Responder who also was a Weekly Responder, i.e., decreased of 30% from baseline for abdominal pain intensity and increased of at least one CSBM (complete spontaneous bowel movement) in the same week for at least 2 of the 4 weeks in month 3 of the Treatment Period.

    Time frame: 12 weeks

  2. Change From Baseline in Stool Consistency

    Change from baseline in stool consistency based upon the Bristol Stool Form Scale (BSFS) Rating 1 to 7. Baseline was the mean BSFS score recorded during the 2-week baseline diary assessment period prior to the first dose of study drug. BSFS Rating 1 to 7: 1. Separate hard lumps, like nuts (hard to pass) 2. Sausage-shaped but lumpy 3. Like a sausage but with cracks on its surface 4. Like a sausage or snake, smooth and soft 5. Soft blobs with clear-cut edges (passed easily) 6. Fluffy pieces with ragged edges, a mushy stool 7. Watery, no solid pieces, entirely liquid

    Time frame: Baseline and 12-Week

  3. Change From Baseline in Straining

    Change from baseline in Straining Score over the 12-week treatment period. Baseline was the mean of non-missing straining scores recorded during the 2-week baseline diary assessment period prior to the first dose of study drug. The severity of straining during a bowel movement was measured using an 11-point scale (0-10 rating; 0 = no straining; 10 = worst straining).

    Time frame: Baseline and 12-week

  4. Change From Baseline in CSBM Frequency Rate

    Change from baseline over the 12-week Treatment Period in CSBM (Complete Spontaneous Bowel Movement) Frequency Rate (CSBMs/Week). Baseline was the mean number of CSBMs recorded during the 2-week baseline diary assessment period prior to the first dose of study drug.

    Time frame: Baseline and 12-Week

  5. Number of Patients With a SBM Within 24 Hours After the First Dose

    Number of patients with a SBM (spontaneous bowel movement) within 24 hours after the first dose of study drug

    Time frame: Up to 24 hours after first dose of study drug

  6. Change From Baseline in Abdominal Pain

    Change from baseline in abdominal pain as measured with an 11-point (0-10) Numerical Rating Scale from 0 (No) to 10 (Worst Possible). Baseline is the mean of non-missing abdominal pain scores recorded during the 2-week baseline diary assessment period prior to the first dose of study drug.

    Time frame: Baseline and 12-Week

07

Results

Posted Jun 14, 2019

Participant flow

Participant flow — Overall Study
MilestoneMatching Placebo3.0 mg Plecanatide6.0 mg Plecanatide
Started354351349
Completed295309293
Not completed594256

Outcome measures

PrimaryNumber of Overall Responders - ITT Population

An Overall Responder was a patient who was a Weekly Responder (i.e., decrease of 30% from baseline for abdominal pain intensity and an increase of at least one complete spontaneous bowel movement in the same week) for at least 6 of the 12 treatment weeks.

Time frame:
12 Weeks
Reported as:
Count of participants · Participants
Number of Overall Responders - ITT Population
ParticipantsMatching Placebo3.0 mg Plecanatide6.0 mg Plecanatide
Number of Overall Responders - ITT Population63106103
PrimaryNumber of Abdominal Pain Responders for at Least 6 of 12 Treatment Weeks

An Abdominal Pain Intensity Responder was a patient who had a decrease of 30% from baseline for abdominal pain intensity. Baseline was the mean of non-missing abdominal pain scores recorded during the 2-week baseline diary assessment period prior to the first dose of study drug.

Time frame:
12 Weeks
Reported as:
Count of participants · Participants
Number of Abdominal Pain Responders for at Least 6 of 12 Treatment Weeks
ParticipantsMatching Placebo3.0 mg Plecanatide6.0 mg Plecanatide
Number of Abdominal Pain Responders for at Least 6 of 12 Treatment Weeks112145156
PrimaryNumber of Stool Frequency Responder for at Least 6 of the 12 Treatment Weeks

A Stool Frequency Responder is defined as a patient who experienced an increase of at least one CSBM (complete spontaneous bowel movement) per week from baseline. Baseline was the mean number of CSBMs recorded during the 2-week baseline diary assessment period prior to the first dose of study drug.

Time frame:
12 weeks
Reported as:
Count of participants · Participants
Number of Stool Frequency Responder for at Least 6 of the 12 Treatment Weeks
ParticipantsMatching Placebo3.0 mg Plecanatide6.0 mg Plecanatide
Number of Stool Frequency Responder for at Least 6 of the 12 Treatment Weeks124169157
SecondaryNumber of Sustained Efficacy Responders

A Sustained Efficacy Responder was a patient who was an Overall Responder who also was a Weekly Responder, i.e., decreased of 30% from baseline for abdominal pain intensity and increased of at least one CSBM (complete spontaneous bowel movement) in the same week for at least 2 of the 4 weeks in month 3 of the Treatment Period.

Time frame:
12 weeks
Reported as:
Count of participants · Participants
Number of Sustained Efficacy Responders
ParticipantsMatching Placebo3.0 mg Plecanatide6.0 mg Plecanatide
Number of Sustained Efficacy Responders619996
SecondaryChange From Baseline in Stool Consistency

Change from baseline in stool consistency based upon the Bristol Stool Form Scale (BSFS) Rating 1 to 7. Baseline was the mean BSFS score recorded during the 2-week baseline diary assessment period prior to the first dose of study drug. BSFS Rating 1 to 7: 1. Separate hard lumps, like nuts (hard to pass) 2. Sausage-shaped but lumpy 3. Like a sausage but with cracks on its surface 4. Like a sausage or snake, smooth and soft 5. Soft blobs with clear-cut edges (passed easily) 6. Fluffy pieces with ragged edges, a mushy stool 7. Watery, no solid pieces, entirely liquid

Time frame:
Baseline and 12-Week
Reported as:
Mean · score on a scale
Change From Baseline in Stool Consistency
score on a scaleMatching Placebo3.0 mg Plecanatide6.0 mg Plecanatide
Baseline2.06 ± 1.0122.02 ± 0.9181.98 ± 0.913
Week 12 change from baseline1.06 ± 1.3571.59 ± 1.5921.86 ± 1.593
SecondaryChange From Baseline in Straining

Change from baseline in Straining Score over the 12-week treatment period. Baseline was the mean of non-missing straining scores recorded during the 2-week baseline diary assessment period prior to the first dose of study drug. The severity of straining during a bowel movement was measured using an 11-point scale (0-10 rating; 0 = no straining; 10 = worst straining).

Time frame:
Baseline and 12-week
Reported as:
Mean · score on a scale
Change From Baseline in Straining
score on a scaleMatching Placebo3.0 mg Plecanatide6.0 mg Plecanatide
Baseline6.39 ± 1.9916.47 ± 1.8286.50 ± 1.822
Week 12 change from baseline-1.87 ± 2.464-2.69 ± 2.422-2.88 ± 2.464
SecondaryChange From Baseline in CSBM Frequency Rate

Change from baseline over the 12-week Treatment Period in CSBM (Complete Spontaneous Bowel Movement) Frequency Rate (CSBMs/Week). Baseline was the mean number of CSBMs recorded during the 2-week baseline diary assessment period prior to the first dose of study drug.

Time frame:
Baseline and 12-Week
Reported as:
Mean · CSBMs per week
Change From Baseline in CSBM Frequency Rate
CSBMs per weekMatching Placebo3.0 mg Plecanatide6.0 mg Plecanatide
Baseline0.23 ± 0.4400.22 ± 0.4650.28 ± 0.527
Week 12 change from baseline0.86 ± 1.9041.46 ± 2.5651.41 ± 2.586
SecondaryNumber of Patients With a SBM Within 24 Hours After the First Dose

Number of patients with a SBM (spontaneous bowel movement) within 24 hours after the first dose of study drug

Time frame:
Up to 24 hours after first dose of study drug
Reported as:
Count of participants · Participants
Number of Patients With a SBM Within 24 Hours After the First Dose
ParticipantsMatching Placebo3.0 mg Plecanatide6.0 mg Plecanatide
Number of Patients With a SBM Within 24 Hours After the First Dose118168175
SecondaryChange From Baseline in Abdominal Pain

Change from baseline in abdominal pain as measured with an 11-point (0-10) Numerical Rating Scale from 0 (No) to 10 (Worst Possible). Baseline is the mean of non-missing abdominal pain scores recorded during the 2-week baseline diary assessment period prior to the first dose of study drug.

Time frame:
Baseline and 12-Week
Reported as:
Mean · score on a scale
Change From Baseline in Abdominal Pain
score on a scaleMatching Placebo3.0 mg Plecanatide6.0 mg Plecanatide
Baseline6.10 ± 1.7935.94 ± 1.7045.95 ± 1.760
Week 12 change from baseline-1.79 ± 2.196-2.11 ± 2.215-2.46 ± 2.370

Adverse events

Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Matching Placebo0/354 (0%)5/354 (1.4%)16/354 (4.5%)
3.0 mg Plecanatide0/351 (0%)4/351 (1.1%)37/351 (10.5%)
6.0 mg Plecanatide2/347 (0.6%)2/347 (0.6%)28/347 (8.1%)
Most frequent serious events
Showing 10 of 12
Most frequent serious events
EventMatching Placebo3.0 mg Plecanatide6.0 mg Plecanatide
Transaminases increasedInvestigations0/3541/3511/347
Affective disorderPsychiatric disorders0/3540/3511/347
Hepatitis CInfections and infestations0/3540/3511/347
LymphadenitisBlood and lymphatic system disorders0/3541/3510/347
DrowningGeneral disorders0/3541/3510/347
Cholecystitis acuteHepatobiliary disorders0/3541/3510/347
Alanine aminotransferase increasedInvestigations1/3540/3510/347
Hepatic enzyme increaseInvestigations1/3540/3510/347
Biplar I disorderPsychiatric disorders1/3540/3510/347
Psychotic disorderPsychiatric disorders1/3540/3510/347
Most frequent other events
Most frequent other events
EventMatching Placebo3.0 mg Plecanatide6.0 mg Plecanatide
DiarrheaGastrointestinal disorders2/35419/35115/347
Urinary tract infectionInfections and infestations4/3544/3517/347
NasopharyngitisInfections and infestations7/3547/3514/347
NauseaGastrointestinal disorders3/3547/3512/347

Baseline characteristics

Age, Continuous
Age, Continuous(years)Matching Placebo3.0 mg Plecanatide6.0 mg PlecanatideTotal
Mean43.0 ± 13.7143.0 ± 13.7643.2 ± 13.3443.1 ± 13.60
Sex: Female, Male
Sex: Female, Male(Participants)Matching Placebo3.0 mg Plecanatide6.0 mg PlecanatideTotal
Female272267266805
Male828483249
08

Study locations

155 sites
  • Synergy Research Site
    Athens, Alabama 35611, United States
  • Synergy Research Site
    Birmingham, Alabama 35242, United States
  • Synergy Research Site
    Dothan, Alabama 36305, United States
  • Synergy Research Site
    Foley, Alabama 36535, United States
  • Synergy Research Site
    Huntsville, Alabama 35801, United States
  • Synergy Research Site
    Montgomery, Alabama 36106, United States
  • Synergy Research Site
    Chandler, Arizona 85224, United States
  • Synergy Research Site
    Glendale, Arizona 85308, United States
  • Synergy Research Site
    Phoenix, Arizona 85018, United States
  • Synergy Research Site
    Tucson, Arizona 85710, United States
  • Synergy Research Site
    Tucson, Arizona 85712, United States
  • Synergy Research Site
    Conway, Arkansas 72034, United States
  • Synergy Research Site
    Little Rock, Arkansas 72211, United States
  • Synergy Research Site
    Little Rock, Arkansas 72212, United States
  • Synergy Research Site
    Anaheim, California 92801, United States
  • Synergy Research Site
    Artesia, California 90701, United States
  • Synergy Research Site
    Chula Vista, California 91910, United States
  • Synergy Research Site
    Corona, California 92879, United States
  • Synergy Research Site
    Encino, California 91436, United States
  • Synergy Research Site
    Fountain Valley, California 92708, United States
  • Synergy Research Site
    Fresno, California 93702, United States
  • Synergy Research Site
    Garden Grove, California 92840, United States
  • Synergy Research Site
    La Mesa, California 91942, United States
  • Synergy Research Site
    La Mirada, California 90638, United States
  • Synergy Research Site
    Laguna Hills, California 92653, United States
  • Synergy Research Site
    Lancaster, California 93534, United States
  • Synergy Research Site
    North Hollywood, California 91606, United States
  • Synergy Research Site
    Sacramento, California 95821, United States
  • Synergy Research Site
    San Bernardino, California 92408, United States
  • Synergy Research Site
    San Diego, California 92103, United States
  • Synergy Research Site
    Thousand Oaks, California 91360, United States
  • Synergy Research Site
    Upland, California 91786, United States
  • Synergy Research Site
    Upland, California, United States
  • Synergy Research Site
    Broomfield, Colorado, United States
  • Synergy Research Site.
    Yosemite Centennial, Colorado 80112, United States
  • Synergy Research Site
    Bristol, Connecticut 06010, United States
  • Synergy Research Site
    Hamden, Connecticut 06518, United States
  • Synergy Research Site
    Boynton Beach, Florida 33426, United States
  • Synergy Research Site
    Bradon, Florida 33511, United States
  • Synergy Research Site
    DeLand, Florida 32720, United States
  • Synergy Research Site
    Fort Lauderdale, Florida 33308, United States
  • Synergy Research Site
    Homestead, Florida 33030, United States
  • Synergy Research Site
    Inverness, Florida 34452, United States
  • Synergy Research Site
    Jacksonville, Florida 32205, United States
  • Synergy Research Site
    Miami, Florida 33144, United States
  • Synergy Research Site
    Miami Lakes, Florida 33014, United States
  • Synergy Research Site
    Miami Springs, Florida 33166, United States
  • Synergy Research Site
    Orlando, Florida 32801, United States
  • Synergy Research Site
    Ormond Beach, Florida 32174, United States
  • Synergy Research Site
    Oviedo, Florida 32765, United States
  • Synergy Research Site
    Port Orange, Florida 32129, United States
  • Synergy Research Site
    St. Petersburg, Florida 33709, United States
  • Synergy Research Site
    Tampa, Florida 33607, United States
  • Synergy Research Site
    Atlanta, Georgia 30328, United States
  • Synergy Research Site
    Marietta, Georgia 30060, United States
  • Synergy Research Site
    Norcross, Georgia 30071, United States
  • Synergy Research Site
    Norcross, Georgia 30092, United States
  • Synergy Research Site
    Stockbridge, Georgia 30281, United States
  • Synergy Research Site
    Idaho Falls, Idaho 83404, United States
  • Synergy Research Site
    Idaho Falls, Idaho, United States
  • Synergy Research Site
    Chicago, Illinois 60611, United States
  • Synergy Research Site
    Evanston, Illinois 60201, United States
  • Synergy Research Site
    Evergreen Park, Illinois 60805, United States
  • Synergy Research Site
    Rockford, Illinois 61107, United States
  • Synergy Research Site
    Evansville, Indiana 47714, United States
  • Synergy Research Site
    Augusta, Kansas 67010, United States
  • Synergy Research Site
    Newton, Kansas 67114, United States
  • Synergy Research Site
    Topeka, Kansas 66606, United States
  • Synergy Research Site
    Wichita, Kansas 67205, United States
  • Synergy Research Site
    Wichita, Kansas 67207, United States
  • Synergy Research Site
    Baton Rouge, Louisiana 70809, United States
  • Synergy Research Site
    Crowley, Louisiana 70526, United States
  • Synergy Research Site
    Mandeville, Louisiana 70448, United States
  • Synergy Research Site
    Metairie, Louisiana 70006, United States
  • Synergy Research Site
    Monroe, Louisiana 71201, United States
  • Synergy Research Site
    New Orleans, Louisiana 70115, United States
  • Synergy Research Site
    Shreveport, Louisiana 71105, United States
  • Synergy Research Site
    Baltimore, Maryland 21215, United States
  • Synergy Research Site
    Hagerstown, Maryland 21742, United States
  • Synergy Research Site
    Boston, Massachusetts 02131, United States
  • Synergy Research Site
    Chesterfield, Michigan 48047, United States
  • Synergy Research Site
    Flint, Michigan 48504, United States
  • Synergy Research Site
    Rochester, Michigan 48307, United States
  • Synergy Research Site
    Wyoming, Michigan 49519, United States
  • Synergy Research Site.
    Jackson, Mississippi, United States
  • Synergy Research Site
    Hazelwood, Missouri 63042, United States
  • Synergy Research Site
    Omaha, Nebraska 68134, United States
  • Synergy Research Site
    Las Vegas, Nevada 89119, United States
  • Synergy Research Site
    Marlton, New Jersey 08053, United States
  • Synergy Research Site
    Albuquerque, New Mexico 87108, United States
  • Synergy Research Site
    Brooklyn, New York 11206, United States
  • Synergy Research Site
    Great Neck, New York 11023, United States
  • Synergy Research Site
    New Windsor, New York 12553, United States
  • Synergy Research Site
    New York, New York 10016, United States
  • Synergy Research Site
    North Massapequa, New York 11758, United States
  • Synergy Research Site
    Asheboro, North Carolina 27203, United States
  • Synergy Research Site
    Cary, North Carolina 27513, United States
  • Synergy Research Site
    Charlotte, North Carolina 28210, United States
  • Synergy Research Site
    Charlotte, North Carolina 28277, United States
  • Synergy Research Site
    Concord, North Carolina 28025, United States

Showing the first 100 of 155 sites. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Brenner DM, Shin AS, Laitman AP, Deutsch JK, Kunkel DC. The Effectiveness of Plecanatide for Treating Constipation and Bloating in Patients Aged 18 to 40 Years With Irritable Bowel Syndrome: Utilization of a New Composite Trisymptom Endpoint. J Gastroenterol Hepatol. 2025 Dec;40(12):2890-2897. doi: 10.1111/jgh.70119. Epub 2025 Nov 10. PubMed 41214272 ↗
  • Cash BD, Sharma A, Walker A, Laitman AP, Chang L. Plecanatide for the treatment of chronic idiopathic constipation and irritable bowel syndrome with constipation: Post hoc analyses of placebo-controlled trials in adults with severe constipation. Neurogastroenterol Motil. 2023 Sep;35(9):e14632. doi: 10.1111/nmo.14632. Epub 2023 Jun 18. PubMed 37332239 ↗
  • Menees SB, Franklin H, Chey WD. Evaluation of Plecanatide for the Treatment of Chronic Idiopathic Constipation and Irritable Bowel Syndrome With Constipation in Patients 65 Years or Older. Clin Ther. 2020 Jul;42(7):1406-1414.e4. doi: 10.1016/j.clinthera.2020.05.012. Epub 2020 Jul 10. PubMed 32660770 ↗
10

Timeline

1 registry update since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2014, a primary completion of Dec 2016 and a completion of Feb 2017. It does not say whether these dates are actual or estimated.

Results were first posted in Jun 2019, 2 years 6 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 20, 2015
First posted
Mar 13, 2015
Start
Dec 2014
Primary completionActual
Dec 2016
CompletionActual
Feb 2017
Results first posted
Jun 14, 2019
Last update
Oct 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
6 sites added, 6 sites removed
Show 6 added (6 United States)
  • Synergy Research Site. · Yosemite Centennial, United States
  • Synergy Research Site · Bradon, United States
  • Synergy Research Site · St. Petersburg, United States
  • Synergy Research Site · Carrolton, United States
  • Synergy Research Site · George, United States
  • Synergy Research Site · Sandy City, United States
Show 6 removed
  • Synergy Research Site. · Centennial, United States
  • Synergy Research Site · Brandon, United States
  • Synergy Research Site · Saint Petersburg, United States
  • Synergy Research Site · Carrollton, United States
  • Synergy Research Site · Saint George, United States
  • Synergy Research Site · Sandy, United States
Oct 20, 2026
Publications
2 publications citing this study linked from PubMed, e.g. PubMed 41214272 ↗
Oct 20, 2026
Title
The Plecanatide Irritable Bowel Syndrome With Constipation Safety and Efficacy Study (IBS-C)
Oct 20, 2026
Show all 1 update
  1. Oct 20, 2026
    Publications 2 publications citing this study linked from PubMed, e.g. PubMed 41214272 ↗
    6 sites added, 6 sites removed
    Show 6 added (6 United States)
    • Synergy Research Site. · Yosemite Centennial, United States
    • Synergy Research Site · Bradon, United States
    • Synergy Research Site · St. Petersburg, United States
    • Synergy Research Site · Carrolton, United States
    • Synergy Research Site · George, United States
    • Synergy Research Site · Sandy City, United States
    Show 6 removed
    • Synergy Research Site. · Centennial, United States
    • Synergy Research Site · Brandon, United States
    • Synergy Research Site · Saint Petersburg, United States
    • Synergy Research Site · Carrollton, United States
    • Synergy Research Site · Saint George, United States
    • Synergy Research Site · Sandy, United States
    Title The Plecanatide Irritable Bowel Syndrome With Constipation Safety and Efficacy Study (IBS-C)
    + 2 other changes: verification date and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT02387359
Responsible party
Sponsor
First posted
Mar 13, 2015
Start date
Dec 2014
Primary completion
Dec 2016
Completion
Feb 2017
Results posted
Jun 14, 2019
Last update
Oct 20, 2026

Study contacts

Paul F.C. Eng, PhD
study director · Synergy Pharmaceuticals Inc.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Plecanatide

Start the discussion